Hims & Hers Health Inc.(HIMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HIMS Hims & Hers Health Inc.

Trading 05-23 13:49:31 EDT

16.05

-0.12

-0.74%

High16.74	Low15.98	Vol6.75M
Open16.74	D1 Closing16.17	Amplitude4.70%
Mkt Cap3.45B	Tradable Cap2.98B	Total Shares214.79M
T/O109.59M	T/O Rate3.63%	Tradable Shares185.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HIMS","market":"US","secType":"STK","nameCN":"Hims & Hers Health Inc.","latestPrice":16.05,"timestamp":1716486567819,"preClose":16.17,"halted":0,"volume":6754569,"delay":0,"floatShares":185962652,"shares":214786086,"eps":-0.011146,"marketStatus":"Trading","change":-0.12,"latestTime":"05-23 13:49:31 EDT","open":16.74,"high":16.74,"low":15.98,"amount":109593928.983195,"amplitude":0.047001,"askPrice":16.06,"askSize":403,"bidPrice":16.04,"bidSize":310,"shortable":3,"etf":0,"ttmEps":-0.011146,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716494400000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":16.17,"preHourTrading":{"tag":"盘前","latestPrice":16.708,"preClose":16.17,"latestTime":"09:29 EDT","volume":106076,"amount":1775370.6752799999,"timestamp":1716470964657},"postHourTrading":{"tag":"盘后","latestPrice":16.68,"preClose":16.17,"latestTime":"19:59 EDT","volume":283114,"amount":4660549.922,"timestamp":1716422379573},"volumeRatio":0.43084,"overnightSupported":true},"requestUrl":"/m/hq/s/HIMS/wiki","defaultTab":"wiki","newsList":[{"id":"2437576729","title":"Boston Scientific (BSX) Rides on Emerging Markets, MedSurg","url":"https://stock-news.laohu8.com/highlight/detail?id=2437576729","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437576729?lang=en_us&edition=fundamental","pubTime":"2024-05-23 22:05","pubTimestamp":1716473100,"startTime":"0","endTime":"0","summary":"Boston Scientific BSX is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2  currently.Boston Scientific Corporation price | Boston Scientific Corporation Quote. On the flip side, the industry-wide trend of difficult macroeconomic conditions in the form of geopolitical pressure leading to disruptions in economic activity, global supply chains and labor markets is creating a challenging business environment for Boston Scientific. International conflicts, including the Russia-Ukraine war and tension between China and Taiwan, have increased cybersecurity risk","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/boston-scientific-bsx-rides-emerging-140500142.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437431767","title":"Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2437431767","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437431767?lang=en_us&edition=fundamental","pubTime":"2024-05-23 22:00","pubTimestamp":1716472800,"startTime":"0","endTime":"0","summary":"Veracyte, Inc. VCYT, a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID  tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape.By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial role in the ongoing effort to personalize cancer treatment, offering hope for better patient outcomes in thyroid cancer care.Veracyte’s comprehensive Afirma solution, consisting of the Afirma GSC  and the Afirma Xpression Atlas, efficiently addresses the complex landscape in thyroid nodule diagnosis. The combined offering aims to provide physicians with clinically actionable results from a single fine needle aspiration or FNA biopsy. An estimated 600,000 people in the United States are said to undergo this procedure each year.Afirm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XuMJ_dsQDMqLc73Q7JGcxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/cd9fa2ca3125c2741152b27cc2930bff","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XuMJ_dsQDMqLc73Q7JGcxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/cd9fa2ca3125c2741152b27cc2930bff"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veracytes-vcyt-findings-advance-thyroid-140000801.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437761618","title":"Globus Medical (GMED) Hits 52-Week High: What's Driving It?","url":"https://stock-news.laohu8.com/highlight/detail?id=2437761618","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437761618?lang=en_us&edition=fundamental","pubTime":"2024-05-23 20:51","pubTimestamp":1716468660,"startTime":"0","endTime":"0","summary":"Shares of Globus Medical GMED reached a new 52-week high of $67.37 on May 22 before closing the session marginally lower at $67.15.In the past year, this Zacks Rank #3  stock has rallied 25.8% compared with the 12.1% growth of the industryand the S&P 500 composite’s rise of 29.5%.Globus Medical has an expected 2024 sales growth rate of 57.8%. Earnings for the year are projected to increase by 20.7% compared with the industry’s 13.3%. The company topped earnings estimates in each of the trailing four quarters, the average beat being 10.8%.Globus Medical is witnessing an upward trend in its stock price, prompted by the strategic NuVasive merger. The optimism led by the robust 2024 first-quarter performance, as well as a rapid cadence of product launches, is expected to contribute to the growth. However, the company faces concerns over adverse macroeconomic impacts and low demand for healthcare products.Steady Pace of Product Development: Globus Medical is consistently making R&D efforts ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cYhdSHZ3kDYVQNhcMTsM_w--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/globus-medical-gmed-hits-52-125100964.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437214053","title":"Hims & Hers Is Selling Copycat Weight-Loss Drugs. Here's How. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2437214053","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437214053?lang=en_us&edition=fundamental","pubTime":"2024-05-23 02:18","pubTimestamp":1716401880,"startTime":"0","endTime":"0","summary":"A plan by Hims & Hers Health to sell legal copies of Novo Nordisk's weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials.Enormous demand has created shortages of Novo's Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.Hims & Hers, known for generic prescription medicines for ailments like erectile dysfunction and hair loss, saw its shares soar 28% on Monday after the company said it would offer an alternative for patients who can't get Wegovy or Zepbound.In a statement to Barron's, Hims & Hers chief medical officer, Dr. Pat Carrol, said that the company agrees with the FDA that patients should ensure they are using a reliable supplier for medications. \"At Hims & Hers, we","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2437190982","title":"Wall Street Lunch: Australia Bans Copycat Weight Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2437190982","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437190982?lang=en_us&edition=fundamental","pubTime":"2024-05-23 01:32","pubTimestamp":1716399120,"startTime":"0","endTime":"0","summary":"Australia to ban compounded versions of Novo Nordisk's semaglutide and Eli Lilly's tirzepatide due to safety concerns.Existing home sales dipped 1.89% in April to 4.14 million.All eyes on Nvidia earnings but BofA points to another stock that deserves the title of AI darling.   apomares/E+ via Getty Images Listen below or on the go on Apple Podcasts and Spotify","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153740646/image_1153740646.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153740646/image_1153740646.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4695051-wall-street-lunch-australia-bans-copycat-weight-loss-drugs","is_publish_highlight":false,"gpt_icon":1},{"id":"2437221567","title":"The Growth Stock Shuffle: 2 to Ditch and 1 to Own","url":"https://stock-news.laohu8.com/highlight/detail?id=2437221567","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2437221567?lang=en_us&edition=fundamental","pubTime":"2024-05-23 00:42","pubTimestamp":1716396147,"startTime":"0","endTime":"0","summary":"Investing in growth stocks requires a keen eye for profitability. Ditch these two unprofitable stocks and embrace this telehealth winner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/the-growth-stock-shuffle-2-to-ditch-and-1-to-own/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437215296","title":"Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes","url":"https://stock-news.laohu8.com/highlight/detail?id=2437215296","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437215296?lang=en_us&edition=fundamental","pubTime":"2024-05-22 23:15","pubTimestamp":1716390900,"startTime":"0","endTime":"0","summary":"Bruker Corporation’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions, and the ongoing portfolio transformation. However, macroeconomic issues dent profit. The stock carries a Zacks Rank #3  currently.Bruker’s CALID business has been gaining from the strong demand for differentiated instruments, particularly in life science mass spectrometry proteomics solutions and optics spectroscopy and microscopy instruments. Bruker’s flagship timsTOF platform is a key driver in life science mass spectrometry, further bolstered by the aftermarket business and the sustained growth in applied mass spectrometry and the optics infrared, near-infrared and Raman business.On the flip side, Bruker generates a substantial portion of its revenues from the international markets, primarily Germany, Switzerland and other countries in the European Union, and Japan. As a result, currency fluctuations continue to result in foreign currency transaction losses at the company. I","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bruker-brkr-gains-market-share-151500917.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437292534","title":"Here's Why You Should Buy Haemonetics (HAE) Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2437292534","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437292534?lang=en_us&edition=fundamental","pubTime":"2024-05-22 21:13","pubTimestamp":1716383580,"startTime":"0","endTime":"0","summary":"Haemonetics HAE is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s hospital portfolio is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism.Meanwhile, headwinds from economic uncertainties and adverse foreign exchange effects are concerns for Haemonetics’ operations.In the past year, this Zacks Rank #2  stock has rallied 11.7% against the 1.3% fall of the industryand a 26.7% increase of the S&P 500 composite.The global provider of blood and plasma supplies and services has a market capitalization of $4.84 billion. HAE surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 13.24%.In December 2023, Haemonetics acquired OpSens. The buyout expands its Hospital business with procedure-enabling technologies in high-growth areas. Following this, OpSens Pressure Sensing Guidewire Technology delivered nearly $1","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GmVc8.ZtfGjPFG_U83F8fA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e34d884fa2c79bf8b02903b1effd4c0b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-buy-haemonetics-hae-131300227.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437929476","title":"Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade","url":"https://stock-news.laohu8.com/highlight/detail?id=2437929476","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437929476?lang=en_us&edition=fundamental","pubTime":"2024-05-22 21:06","pubTimestamp":1716383160,"startTime":"0","endTime":"0","summary":"Medtronic plc’s MDT most advanced automated insulin delivery  system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. This marks the fourth consecutive year the company has been featured on the list, with previous honors received for GI Genius, the Micra leadless pacemaker and Medtronic LABS.Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation for good. The latest development is expected to significantly boost Medtronic’s Diabetes business.Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes. Medtronic’s MiniMed 780G stands out as the only system to feature meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.T","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medtronics-mdt-minimed-780g-aid-130600864.html","is_publish_highlight":false,"gpt_icon":0},{"id":"1195759274","title":"Pre-Bell｜U.S. Futures Slip as Nvidia Earnings Loom; Temu Owner PDD Jumps 6%; Target Tumbles 8%; Tesla Drops 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195759274","media":"Tiger Newspress","top":-1,"share":"https://ttm.financial/m/news/1195759274?lang=en_us&edition=fundamental","pubTime":"2024-05-22 20:27","pubTimestamp":1716380859,"startTime":"0","endTime":"0","summary":"U.S. stock futures slipped Wednesday as investors looked ahead to the widely-anticipated release of Nvidia’s latest earnings report.Market SnapshotAt 08:24 a.m. ET, Dow Jones Industrial Average future","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"gpt_icon":1},{"id":"2437399264","title":"Hims & Hers cut to Neutral at Citi on recent rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2437399264","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437399264?lang=en_us&edition=fundamental","pubTime":"2024-05-22 19:51","pubTimestamp":1716378698,"startTime":"0","endTime":"0","summary":"Hims & Hers Health  traded lower premarket Wednesday as Citi downgraded the stock, citing its recent upsurge following an announcement to sell cheaper versions of Novo Nordisk's  popular weight loss therapy, semaglutide. Citi analyst Daniel Grosslight noted that Hims has added 20% since Monday, when the company announced its decision to sell so-called compounded versions of the GLP-1 receptor agonist, which is currently in short supply amid soaring demand. While there is limited information on the move, with the company adding roughly $760M of enterprise value, there is \"little room for upside,\" Grosslight wrote as he downgraded Hims  to Neutral from Buy. \"The bigger question in our mind, though, is what happens after the branded GLP-1s come off the shortage list?\" the analyst added. \"At that point, in our view, it will be much harder for HIMS to compound, creating significant uncertainty around the durability of this earnings stream.\" However, Grosslight raised his price target on HIM","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4109224-hims-hers-stock-downgraded-citi-valuation","is_publish_highlight":false,"gpt_icon":0},{"id":"2437633392","title":"Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2437633392","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437633392?lang=en_us&edition=fundamental","pubTime":"2024-05-22 18:52","pubTimestamp":1716375147,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":1},{"id":"2437327952","title":"U.S. RESEARCH ROUNDUP- Ameriprise Financial, Dell Technologies, Tyler Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2437327952","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437327952?lang=en_us&edition=fundamental","pubTime":"2024-05-22 15:31","pubTimestamp":1716363098,"startTime":"0","endTime":"0","summary":"May 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ameriprise Financial, Dell Technologies and Tyler Technologies on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437287128","title":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437287128","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437287128?lang=en_us&edition=fundamental","pubTime":"2024-05-22 12:50","pubTimestamp":1716353453,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS – Research Report), Hims & He...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-hims-hers-health-hims-and-cytokinetics-cytk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pyxis-oncology-pyxs-hims-hers-health-hims-and-cytokinetics-cytk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437608428","title":"Evolus (EOLS) Releases Favorable Dermal Fillers Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2437608428","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437608428?lang=en_us&edition=fundamental","pubTime":"2024-05-21 22:57","pubTimestamp":1716303420,"startTime":"0","endTime":"0","summary":"Evolus, Inc. EOLS has announced favorable results from its pivotal U.S. nasolabial fold  study of dermal filler products, Evolysse Lift and Smooth. Presented at the 2024 SCALE Meeting, these results represent a significant milestone in the company’s strategic expansion within the aesthetic device market.These promising results bolster the company’s upcoming Premarket Approval Application  for the U.S. launch of Evolus’s dermal filler lines. Evolus plans to submit the PMA applications for Evolysse Lift and Smooth within 90 days.The addition of Evolysse fillers to the company’s portfolio will perfectly complement Evolus’ flagship neurotoxin Jeuveau, which claims to be the fastest growing neurotoxin in the United States for the past three years. Evolysse with Jeuveau is projected to increase Evolus' total addressable market by 78%.This expansion positions Evolus as a more formidable player in the aesthetics sector, catering to a broader range of consumer needs.Some better-ranked stocks in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z584cE9dmmrKrF4Y5puxGg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/fcaf2bfdd08336aba6c54d27476b6e54","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z584cE9dmmrKrF4Y5puxGg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/fcaf2bfdd08336aba6c54d27476b6e54"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evolus-eols-releases-favorable-dermal-145700401.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437426174","title":"Here's Why You Should Hold on to Abbott (ABT) Stock for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2437426174","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437426174?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:29","pubTimestamp":1716298140,"startTime":"0","endTime":"0","summary":"Abbott Laboratories is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s solid sales trajectory is encouraging and should continue to sustain with several new growth opportunities. Strong potential in the Diagnostics space is highly promising as well.However, the company faces challenges from lower demand for COVID-19 testing, which is hurting growth, as well as adverse currency movements.In the past year, this Zacks Rank #3  stock has declined 4.4% compared with a 0.6% fall of the industry and a 26.6% rise of the S&P 500 composite.This renowned provider of a diversified line of healthcare products has a market capitalization of $181.08 billion. Abbott’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.4%.The company has been investing in science-based solutions to address the growing global","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-hold-abbott-abt-132900987.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437944855","title":"Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds","url":"https://stock-news.laohu8.com/highlight/detail?id=2437944855","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437944855?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:21","pubTimestamp":1716297717,"startTime":"0","endTime":"0","summary":"Mangoceuticals , a microcap with a market cap of ~$6M, is up ~110% in premarket trading after saying it will launch proprietary oral versions of GLP-1 weight loss drugs semaglutide and tirzepatide. Semaglutide, in injectable form, is sold as Wegovy by Novo Nordisk , while tirzepatide is sold as Zepbound by Eli Lilly .  Mangoceuticals said the oral dissolvable tablets will be available through its telemedicine platform starting in Q3. Oral semaglutide, which the company is marketing as \"Slim,\" will cost $299 a month, while oral tirzepatide, marketed as \"Trim,\" goes for $399 a month. \"The oral formulations of Semaglutide and Tirzepatide are designed for daily consumption and are expected to provide similar weight loss benefits without the need for regular injections,\" Mangoceuticals  said in a news release. Both Novo Nordisk  and Lilly  are slightly higher in premarket trading. The announcement comes a day after Hims & Hers Health  stock jumped after announcing it would sell cheap compou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108784-microcap-mangoceuticals-doubles-on-plan-to-sell-cheap-oral-glp-1-weight-loss-meds","is_publish_highlight":false,"gpt_icon":1},{"id":"2437412859","title":"Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2437412859","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437412859?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:15","pubTimestamp":1716293700,"startTime":"0","endTime":"0","summary":"Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs.The company aims to c","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/145057072/image_145057072.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/145057072/image_145057072.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694747-hims-and-hers-stock-access-compounded-glp-1-drugs-further-volatility-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2437419868","title":"Wall Street Breakfast: The Winning Medal","url":"https://stock-news.laohu8.com/highlight/detail?id=2437419868","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437419868?lang=en_us&edition=fundamental","pubTime":"2024-05-21 19:30","pubTimestamp":1716291045,"startTime":"0","endTime":"0","summary":"The commodity competition can experience chaotic events, with scandals and manipulation hitting items like nickel and cocoa in recent years. There is speculation that this might be going on this time around, triggered by leveraged contract buying, short squeeze momentum, or price premiums on different exchanges. Others see a lot of metal potential that has even resulted in some real-world M&A action, such as BHP's  $39B proposed takeover of Anglo American , which would create the world's top copper producer. Wall Street leadership Succession plans are \"well on the way\" at JPMorgan , with Jamie Dimon saying it's up to the board to determine how much longer he'll remain CEO. \"I think when I can't put the jersey on and give it my full effort, I should leave,\" he announced at the bank's Investor Day, adding that the timetable \"is not five years anymore.\" Dimon also outlined that the lender will not repurchase a lot of stock at current prices, noting that such a buyback - at a valuation of ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226694690/image_1226694690.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1226694690/image_1226694690.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4694739-wall-street-breakfast-winning-medal","is_publish_highlight":false,"gpt_icon":0},{"id":"2437416458","title":"Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell; Hims & Hers Health to Advance, AMC Entertainment to Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2437416458","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437416458?lang=en_us&edition=fundamental","pubTime":"2024-05-21 19:00","pubTimestamp":1716289227,"startTime":"0","endTime":"0","summary":"The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Tuesday's opening bell. Hims & Hers Health (HIMS) was up 2.5% pre-bell, advancing further after a 27.7% rally","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.1684},{"period":"1month","weight":0.3611},{"period":"3month","weight":0.7111},{"period":"6month","weight":0.9672},{"period":"1year","weight":0.7576},{"period":"ytd","weight":0.8169}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":0.0603},{"period":"3month","weight":0.044},{"period":"6month","weight":0.1637},{"period":"1year","weight":0.2795},{"period":"ytd","weight":0.1147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oaktree Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the industrial and consumer sectors. The company was founded in 2019 and is based in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.06333},{"month":2,"riseRate":0.6,"avgChangeRate":0.143326},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00162},{"month":4,"riseRate":0.2,"avgChangeRate":-0.059815},{"month":5,"riseRate":0.4,"avgChangeRate":0.036354},{"month":6,"riseRate":0.75,"avgChangeRate":-0.011926},{"month":7,"riseRate":0.5,"avgChangeRate":0.014959},{"month":8,"riseRate":0.5,"avgChangeRate":-0.052701},{"month":9,"riseRate":0.25,"avgChangeRate":-0.0268},{"month":10,"riseRate":0.2,"avgChangeRate":-0.067321},{"month":11,"riseRate":0.8,"avgChangeRate":0.145964},{"month":12,"riseRate":0.6,"avgChangeRate":0.084497}],"exchange":"NYSE","name":"Hims & Hers Health Inc.","nameEN":"Hims & Hers Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hims & Hers Health Inc.(HIMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Hims & Hers Health Inc.(HIMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Hims & Hers Health Inc.,HIMS,Hims & Hers Health Inc.股票,Hims & Hers Health Inc.股票老虎,Hims & Hers Health Inc.股票老虎国际,Hims & Hers Health Inc.行情,Hims & Hers Health Inc.股票行情,Hims & Hers Health Inc.股价,Hims & Hers Health Inc.股市,Hims & Hers Health Inc.股票价格,Hims & Hers Health Inc.股票交易,Hims & Hers Health Inc.股票购买,Hims & Hers Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hims & Hers Health Inc.(HIMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Hims & Hers Health Inc.(HIMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction